In a nutshell This article looked at the effectiveness of dulaglutide (Trulicity) compared to insulin glargine (Lantus) for patients with uncontrolled type 2 diabetes (T2D). This study concluded that dulaglutide is more effective for these patients compared to insulin glargine. Some background Metformin is recommended as a first-line treatment for...
Read MoreRecent HbA1C value-Above 7 Posts on Medivizor
Evaluating Glyxambi for patients with Type 2 diabetes
In a nutshell This study evaluated empagliflozin (Jardiance) and linagliptin (Tradjenta) for the treatment of Type 2 diabetes (T2D). This study found that combining both drugs (Glyxambi) was more effective at lowering blood glucose levels than either medication alone, with similar side effects. Some background For patients with T2D, the...
Read MoreEvaluating a combination therapy for the treatment of type 2 diabetes
In a nutshell This study evaluated the safety and effectiveness of a combination treatment between sodium-glucose cotransporter 2 (SGLT) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists for patients with Type 2 diabetes (T2D). This study concluded that combination treatment improved blood glucose control and reduced weight loss for...
Read MoreEvaluating combination therapy versus metformin only for patients with Type 2 diabetes
In a nutshell This study evaluated whether adding vildagliptin (Galvus) to metformin (Glucophage) could improve the duration of blood glucose control for patients with newly diagnosed Type 2 Diabetes (T2D). The authors found that this treatment combination improved long-term blood glucose control for these patients. Some background...
Read MoreEvaluating oral semaglutide compared to liraglutide injection in patients with type 2 diabetes
In a nutshell This study compared the safety and effectiveness of oral semaglutide with liraglutide administered via subcutaneous (under the skin) injection in patients with type 2 diabetes (T2D). The authors concluded that both treatments were similarly safe and effective in these patients. Some background Glucagon-like-peptide-1 (GLP1)...
Read MoreLong-term outcomes of pioglitazone plus insulin in patients with type 2 diabetes
In a nutshell This study evaluated the impact of long-term pioglitazone (Actos) treatment on outcomes for patients with type 2 diabetes (T2D) taking insulin. The authors concluded that this treatment lowered mortality risk for these patients. Some background As T2D progresses, more intensive treatment may be required. Typically, this means increasing...
Read MoreLooking for patients with poorly controlled type 2 diabetes to try the EndoBarrier System
In a nutshell This study is investigating the safety and effectiveness of the EndoBarrier system for patients with poorly controlled type 2 diabetes (T2D) and obesity. The main outcome to be measured will be the change in blood glucose levels. This trial is recruiting in multiple locations across the United States. The details Bariatric surgery is the...
Read MoreIs IDegLira more effective than degludec or liraglutide alone for treating uncontrolled Type 2 diabetes?
In a nutshell This study compared IDegLira (Xultophy) to insulin degludec (Tresiba) or liraglutide (Victoza) alone in patients with uncontrolled Type 2 diabetes (T2D). The authors concluded that combined IDegLira was more effective and had fewer side effects than either insulin medication alone. Some background One of the main...
Read MoreLooking for patients with Type 2 diabetes to test a new treatment dose
In a nutshell This study is comparing the effectiveness of two different doses of semaglutide (Ozempic) in patients with Type 2 diabetes (T2D). The main outcome to be measured will be the change in HbA1c (average blood glucose levels over 3 months). The details One of the goals of treatment for patients with T2D is to improve glycemic (blood...
Read MoreLooking for patients with poorly controlled type 2 diabetes to test a new treatment combination
In a nutshell This trial is examining the effectiveness of a fixed combination of insulin degludec and liraglutide (IDegLira) for type 2 diabetes (T2D). The main outcome to be measured will be a change in HbA1c (test measuring blood glucose control over the past 3 months). This study is being conducted in Georgia, United States. The...
Read MoreWeight management programme led by family doctors for reversing type 2 diabetes
In a nutshell The aim of this study was to assess the remission of type 2 diabetes (T2D) during a family doctor-led weight management programme. The main finding of the study was that after 2 years of the programme more than one-third of patients had reversed their T2D. Some background The number of people with T2D is increasing. One factor is the...
Read MoreLooking for patients with type 2 diabetes to test new treatment efpeglenatide
In a nutshell This trial is examining the safety and effectiveness of efpeglenatide versus dulaglutide in patients with poorly controlled type 2 diabetes (T2D) who are on metformin. The main outcome to be measured will be a change in HbA1c (blood test measuring average blood glucose over the past 3 months). This trial is being conducted in the United...
Read More
